Obese patients with atrial fibrillation are more efficiently protected from thrombosis under warfarin or xabans compared to non-obese patients; a systematic review and Meta-analysis of six randomized controlled trials
Recommendations about proper anticoagulation in obese patients, body mass index (BMI) > 30 kg/m2, are not yet clearly defined. Obese patients were included in randomized controlled trials comparing new anticoagulants (NOACs) with warfarin in patients with atrial fibrillation or thromboembolism. (Source: Thrombosis Research)
Source: Thrombosis Research - April 23, 2024 Category: Hematology Authors: Lazaros Karatisidis, Konstantinos Zagoridis, Theodoros Mprotsis, Christina Misidou, Aikaterini Pentidou, George Vrachiolias, Zoi Bezirgianidou, Emmanouil Kontomanolis, Emmanouil Spanoudakis Source Type: research
DOACs for older adults with atrial fibrillation and falls: Results from the prospective single-centre DOAFF study
Falls are one of the most fearsome events in anticoagulated older adults. The evidence concerning safety of direct oral anticoagulants (DOACs) in falling elderly patients with atrial fibrillation (AF) is still limited. (Source: Thrombosis Research)
Source: Thrombosis Research - April 23, 2024 Category: Hematology Authors: Filippo Catalani, Lavinia Maria Alessandra Patetta, Elena Campello, Riccardo Fino, Stefano Novello, Giuseppina Occhipinti, Bruno Micael Zanforlini, Paolo Simioni, Giuseppe Sergi Tags: Full Length Article Source Type: research
Modern imaging of acute pulmonary embolism
The first-choice imaging test for visualization of thromboemboli in the pulmonary vasculature in patients with suspected acute pulmonary embolism (PE) is multidetector computed tomography pulmonary angiography (CTPA) – a readily available and widely used imaging technique. Through technological advancements over the past years, alternative imaging techniques for the diagnosis of PE have become available, whilst others are still under investigation. In particular, the evolution of artificial intelligence (AI) i s expected to enable further innovation in diagnostic management of PE. (Source: Thrombosis Research)
Source: Thrombosis Research - April 22, 2024 Category: Hematology Authors: C.M.M. de Jong, L.J.M. Kroft, T.E. van Mens, M.V. Huisman, J.L. St öger, F.A. Klok Tags: Full Length Article Source Type: research
Longitudinal assessment of coagulation potential before, during, and following an in vitro fertilization cycle
The association between estrogen and hypercoagulability is well-established but little is known about coagulation dynamics during IVF. Our goal was to measure coagulation potential prior to, during, and following an IVF cycle and to investigate differences by conception outcome. (Source: Thrombosis Research)
Source: Thrombosis Research - April 20, 2024 Category: Hematology Authors: Carleigh Nesbit, Cemile Gunalp, Jiahui Zhang, Elizabeth McGee, Ira Bernstein, Thomas Orfeo, Maria Cristina Bravo Tags: Full Length Article Source Type: research
Subclass phenotypes in patients with unprovoked venous thromboembolisms using a latent class analysis
Patients with unprovoked venous thromboembolisms (VTEs) can be sub-classified based on the different phenotypes using a latent class analysis (LCA), which might be useful for selecting individual management strategies. (Source: Thrombosis Research)
Source: Thrombosis Research - April 18, 2024 Category: Hematology Authors: Shinya Ikeda, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Kazuhisa Kaneda, Yuji Nishimoto, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase, Shuhei Tsuji, Maki Oi, Takuma Takada, Kazunori Otsui, Jiro Sakamoto, Yos Tags: Full Length Article Source Type: research
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results
D-dimer testing may help deciding the duration of anticoagulation in subjects at high risk of venous thromboembolism (VTE) recurrence. Two management studies on this issue have been published (DULCIS in 2014 and APIDULCIS in 2022). They had similar designs but had important different results. Aim of this article is to compare their results. (Source: Thrombosis Research)
Source: Thrombosis Research - April 18, 2024 Category: Hematology Authors: Gualtiero Palareti, Cristina Legnani, Alberto Tosetto, Daniela Poli, Sophie Testa, Walter Ageno, Vittorio Pengo, Benilde Cosmi, Paolo Prandoni Tags: Full Length Article Source Type: research
Peak plasma anti-Xa direct oral anticoagulant levels after gastrointestinal surgeries: A retrospective cohort
Direct oral anticoagulants (DOACs) are first line treatment for venous thromboembolism (VTE) and non-valvular atrial fibrillation [1]. Absorption of DOACs may be decreased in patients with prior surgery involving removal or rearrangement of the proximal GI tract, due to bypassing absorptive surfaces, changes to gastric emptying, or altered acidity [2]. Decreased DOAC absorption may result in a lower anticoagulant effect and therefore increased risk of thrombosis. Plasma DOAC levels can be tested, but no validated therapeutic ranges exist [3]. (Source: Thrombosis Research)
Source: Thrombosis Research - April 18, 2024 Category: Hematology Authors: Menal Huroy, Rita Selby, Subir Sutradhar, Jean-Philippe Galanaud, Jameel Abdulrehman Tags: Letter to the Editors-in-Chief Source Type: research
The procoagulant signature of cancer cells drives fibrin network formation in tumor microenvironment and impacts its quality. Implications in cancer cell migration and the resistance to anticancer agents
Cancer cells induce hypercoagulability in the tumoral microenvironment by expressing Tissue Factor (TF). We aimed to study the impact of the procoagulant signature of cancer cells on the quality and structure of fibrin network. We also studied the impact of fibrin clot shield (FCS) on the efficiency of anticancer agents and the migration of cancer cells. (Source: Thrombosis Research)
Source: Thrombosis Research - April 16, 2024 Category: Hematology Authors: Huong Chi Mai Tran, Elisabeth Mbemba, No émie Mourot, Beshoy Faltas, Aurélie Rousseau, Elmina Lefkou, Michèle Sabbah, Patrick Van Dreden, Grigoris Gerotziafas Tags: Full Length Article Source Type: research
Platelet Fc γRIIA: An emerging regulator and biomarker in cardiovascular disease and cancer
Platelets, anucleate blood cells derive from megakaryocytes, are involved in cardiovascular diseases and tumors. Fc γRIIA, the only FcγR expressed on human platelets, is known for its role in immune-related diseases. A growing body of evidence reveals that platelet FcγRIIA is a potential target for the prevention and control of cardiovascular disease and cancer, and is an advantageous biomarker. In this review , we describe the structure and physiological function of platelet FcγRIIA, its regulatory role in cardiovascular disease and cancer, and its potential clinical application. (Source: Thrombosis Research)
Source: Thrombosis Research - April 16, 2024 Category: Hematology Authors: Qingsong Zhang, Wenxian Li, Xin Mao, Shuo Miao Tags: Short review Source Type: research
WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIb α receptor
Hypolipidemia and platelet activation play key roles in atherosclerotic diseases. Pirinixic acid (WY-14643) was originally developed as a lipid-lowering drug. Here we focused on its antiplatelet and antithrombotic abilities and the underlying mechanism. (Source: Thrombosis Research)
Source: Thrombosis Research - April 14, 2024 Category: Hematology Authors: Chen Cao, Qingyuan Yang, Xiaoshuang Xia, Zhuangzhuang Chen, Peilin Liu, Xiaowen Wu, Hu Hu, Zhongren Ding, Xin Li Source Type: research
Characterization of a canine freeze-dried platelet-derived hemostatic agent: A preclinical model for surgical and traumatic hemorrhage
A freeze-dried, platelet-derived hemostatic agent (FPH) was developed for acute hemorrhage. The canine product (cFPH) was developed for use in preclinical models supporting human product (hFPH) investigations. (Source: Thrombosis Research)
Source: Thrombosis Research - April 14, 2024 Category: Hematology Authors: Meredith Brown, Benjamin Kuhn, Keith A. Moskowitz, Stephen Amos, Erin Long Mays, W. Allan Alexander, G. Michael Fitzpatrick Source Type: research
Oral anticoagulant therapy in older adults
Patients aged ≥65 years not only account for the majority of patients with atrial fibrillation (AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity, mortality, and undertreatment than younger patients. Several age-related physiological changes with effects on drug pharmacokinetic s/−dynamics and blood vessel fragility as well as the higher prevalence of geriatric conditions such as frailty, multimorbidity, polypharmacy, fall risk, dementia, and malnutrition make older persons more vulnerable to disease- and anticoagulation-related complications. (Source: Thrombosis Research)
Source: Thrombosis Research - April 13, 2024 Category: Hematology Authors: J. Stuby, M. Haschke, T. Tritschler, D. Aujesky Source Type: research
Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting
In this study, we aimed to obtain real-world evidence on the clinical and economic aspects and associated burdens experienced by patients with hemophilia A with inhibitors undergoing ITI in Korea. (Source: Thrombosis Research)
Source: Thrombosis Research - April 12, 2024 Category: Hematology Authors: Ah-Young Kim, Hee Jo Baek, Sukhyang Lee, Eunjung Choo, Young Shil Park, Hankil Lee Tags: Full Length Article Source Type: research
Acute phase determinant of post-thrombotic syndrome: A review of the literature
Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are being evaluated to prevent or to treat PTS. Identifying the patients most likely to benefit from these therapies presents a significant challenge. (Source: Thrombosis Research)
Source: Thrombosis Research - April 11, 2024 Category: Hematology Authors: Lina Khider, Benjamin Planquette, David Smadja, Olivier Sanchez, Carla Rial, Guillaume Goudot, Emmanuel Messas, Tristan Mirault, Nicolas Gendron Tags: Review Article Source Type: research
Small intestinal angiodysplasia and hemorrhage associated with acquired von Willebrand syndrome type 2A secondary to multiple myeloma: Reversal after treatment with IRD regimen (a case report and a brief review of the literature)
Acquired von Willebrand syndrome (AVWS) is a rare acquired hemorrhagic disorder, characterized by qualitative or quantitative deficiencies in von Willebrand factor (VWF), which is easily misdiagnosed as a genetic von Willebrand disease (VWD) and probably underdiagnosed [1,2]. Usually, the diagnosis of AVWS is complicated, and both clinical and case history evaluation as well as laboratory results are required for discerning AVWS from inherited VWD [2,3]. Here we report a case of AVWS secondary to IgA-kappa type of multiple myeloma (MM), found that the existence of anti-VWF autoantibodies (IgG type) in plasma may contribute...
Source: Thrombosis Research - April 11, 2024 Category: Hematology Authors: Yuxin Zhang, Xuquan Zhou, Yujie Guo, Yongning Gao, Zhiyun Niu, Yi Wu, Yan Wang, Jingyu Zhang Tags: Letter to the Editors-in-Chief Source Type: research
